Page last updated: 2024-12-05
tetrachlorodian
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tetrachlorodian: used in the manufacture of synthetic resins [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6619 |
| CHEMBL ID | 1738928 |
| CHEBI ID | 35004 |
| SCHEMBL ID | 19109 |
| MeSH ID | M0122251 |
Synonyms (90)
| Synonym |
|---|
| BIDD:ER0632 |
| AKOS015848853 |
| phenol, 4,4'-isopropylidenebis[2,6-dichloro- |
| phenol, 4,4'-(1-methylethylidene)bis[2,6-dichloro- |
| 4,4'-propane-2,2-diylbis(2,6-dichlorophenol) |
| 4,4'-isopropylidenebis(2,6-dichlorophenol) |
| nsc-67465 |
| nsc67465 |
| hsdb 2921 |
| phenol, 4,4'-isopropylidenebis(dichloro- |
| phenol, 4,4'-(1-methylethylidene)bis(dichloro- |
| phenol, 4,4'-(1-methylethylidene)bis(2,6-dichloro- |
| tetrachlorodian [czech] |
| tetrachlordian [czech] |
| 4,4'-(1-methylethylidene)bis(2,6-dichlorophenol) |
| ai3-25181 |
| 2,2',6,6'-tetrachlorobisphenol a |
| phenol, 4,4'-isopropylidenebis(2,6-dichloro- |
| einecs 201-237-4 |
| nsc 18248 |
| 2,2-bis(3,5-dichloro-4-oxyphenyl)propane |
| 3,5,3',5'-tetrachlorobisphenol a |
| brn 2059573 |
| 2,2-bis(3,5-dichloro-4-hydroxyphenyl)propane |
| 2,2',6,6'-tetrachloro-4,4'-isopropylidenediphenol |
| 3,3',5'-tetrachlorobisphenol a |
| phenol,4'-(1-methylethylidene)bis[2,6-dichloro- |
| 2,5-dichloro-4-oxyphenyl]propane |
| 2,6,6'-tetrachlorobisphenol a |
| phenol,4'-isopropylidenebis[2,6-dichloro- |
| nsc18248 |
| wln: qr bg fg dx1&1&r dq bg fg |
| 3,5,5'-tetrachlorobisphenol a |
| 4,6-dichlorophenol] |
| phenol,4'-(1-methylethylidene)bis[dichloro- |
| 2,5-dichloro-4-hydroxyphenyl)propane |
| tetrachlorodian |
| nsc-18248 |
| 4,6-dichlorophenol) |
| 2,5-dichlorophenyl)propane |
| tetrachlorobisphenol a |
| 79-95-8 |
| tetrachlordian |
| phenol,4'-isopropylidenebis[dichloro- |
| OPREA1_746572 |
| 3,3',5,5'-tetrachlorobisphenol a |
| 2,2-bis(4-hydroxy-3,5-dichlorophenyl)propane |
| inchi=1/c15h12cl4o2/c1-15(2,7-3-9(16)13(20)10(17)4-7)8-5-11(18)14(21)12(19)6-8/h3-6,20-21h,1-2h |
| 2,6-dichloro-4-[2-(3,5-dichloro-4-hydroxyphenyl)propan-2-yl]phenol |
| T0062 |
| NCGC00248700-01 |
| chebi:35004 , |
| CHEMBL1738928 |
| XDH , |
| tox21_303582 |
| dtxcid601770 |
| dtxsid3021770 , |
| NCGC00257461-01 |
| cas-79-95-8 |
| NCGC00258111-01 |
| tox21_200557 |
| FT-0674943 |
| unii-fo0p9et4bn |
| fo0p9et4bn , |
| 3-06-00-05462 (beilstein handbook reference) |
| 4,4'-(1-methylethylidene)bis[2,6-dichlorophenol |
| 4,4'- (1-methylethylidene)bis(2,6-dichlorophenol) |
| 2,2',6,6'-tetrachlorobisphenol a [hsdb] |
| 2,6-dichloro-4-[1-(3,5-dichloro-4-hydroxy-phenyl)-1-methyl-ethyl]phenol |
| SCHEMBL19109 |
| 3OSI |
| 2,2-bis-(3,5-dichloro-4-hydroxyphenyl)-propane |
| 2,2-bis(3,5-dichloro-4-hydroxy-phenyl)propane |
| mfcd00002178 |
| 4,4'-isopropylidene bis(2,6-dichlorophenol) |
| 4,4'-isopropylidenebis[2,6-dichlorophenol] |
| 4,4'-isopropylidene-2,2',6,6'-tetrachlorodiphenol |
| phenol, 4,4'-(2,2-propanediyl) bis[2,6-dichloro]- |
| 2,2-bis[3,5-dichloro-4-oxyphenyl]propane |
| 4MGB |
| tetrachlorobisphenol a, analytical standard |
| 4,4'-(propane-2,2-diyl)bis(2,6-dichlorophenol) |
| bp_16 |
| Q27116363 |
| tetrachloro bisphenol a |
| 3,5,3',5'-tetrachloro-4,4'-dihydroxy-diphenyl-dimethl-methane |
| D92294 |
| tetrachlorobisphenola |
| 4,4 inverted exclamation mark -isopropylidenebis(2,6-dichlorophenol) |
| CS-0213235 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tetrabromobisphenol A and tetrachlorobisphenol A are halogenated bisphenol A (H-BPA), and has raised concerns about their adverse effects on the development of fetuses and infants, however, the molecular mechanisms are unclear, and related metabolomics studies are limited." | ( Metabolomics approach reveals metabolic disorders and potential biomarkers associated with the developmental toxicity of tetrabromobisphenol A and tetrachlorobisphenol A. Chen, Y; Chi, Y; Dong, S; Huang, Q; Lin, Y; Wang, HO; Ye, G; Ye, T, 2016) | 0.43 |
| " However, its toxic effects on animals and humans are not fully understood." | ( The Toxic Effects of Tetrachlorobisphenol A in Saccharomyces cerevisiae Cells via Metabolic Interference. Ji, Z; Li, H; Song, M; Tian, J; Wang, F, 2017) | 0.46 |
| "Tetrachlorobisphenol A (TCBPA), which is widely used as flame retardant, can be released into various environments, thereby being absorbed by wildlife or human beings through food chain's bio-magnification and causing some adverse influences on wildlife or human beings." | ( Oxidative stress and cytotoxicity induced by tetrachlorobisphenol A in Saccharomyces cerevisiae cells. Ji, Z; Li, H; Song, M; Tian, J; Wang, F; Zhang, Y, 2018) | 0.48 |
| "Tetrabromobisphenol A (TBBPA) and tetrachlorobisphenol A (TCBPA) are persistent toxic environmental pollutants that cause severe reproductive toxicity in animals." | ( Differences in reproductive toxicity of TBBPA and TCBPA exposure in male Rana nigromaculata. Chen, B; Chen, F; Du, Q; He, J; Jia, X; Li, N; Liu, W; Shan, X; Tang, J; Zhang, H, 2018) | 0.48 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "04 4 wt% and catalyst dosage of 5 g L(-1), TCBPA with an initial concentration of 20 μM was completely transformed within 60 min, and BPA was detected as the major product through the reaction time." | ( Reductive dechlorination of tetrachlorobisphenol A by Pd/Fe bimetallic catalysts. Huang, Q; Huang, W; Liu, W; Peng, P, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| bisphenol | By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (30)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 89.3584 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 77.5080 | 0.0025 | 41.7960 | 15,848.9004 | AID1347397; AID1347398 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 55.6803 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 68.5896 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 35.6669 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 55.2307 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 11.2588 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 61.1306 | 0.0010 | 22.6508 | 76.6163 | AID1224839 |
| progesterone receptor | Homo sapiens (human) | Potency | 5.7765 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 24.7217 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 61.1306 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 57.7110 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 45.7093 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 48.8799 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 33.1279 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 8.0958 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 54.4827 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 48.5577 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 61.6825 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 33.4789 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 43.6679 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 30.8152 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 42.3425 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 51.6076 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 17.6495 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 49.6137 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 62.3877 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 49.6137 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 (µMol) | 6.0000 | 0.7000 | 3.3500 | 6.0000 | AID977608 |
| Chain A, Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 (µMol) | 6.0000 | 0.7000 | 3.3500 | 6.0000 | AID977608 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (20)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID752865 | Inhibition of sarco/endoplasmic reticulum calcium ATPase in human GM08333 cells assessed as inhibition of calcium ion uptake at 50 uM measured for 1 min by Fura-2AM staining assay | 2013 | Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13 | Structural requirements for inhibitory effects of bisphenols on the activity of the sarco/endoplasmic reticulum calcium ATPase. |
| AID752867 | Inhibition of rabbit skeletal muscle sarco/endoplasmic reticulum calcium ATPase assessed as inhibition of ATP hydrolysis by spectrophotometric analysis | 2013 | Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13 | Structural requirements for inhibitory effects of bisphenols on the activity of the sarco/endoplasmic reticulum calcium ATPase. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2011 | Environmental health perspectives, Sep, Volume: 119, Issue:9 | Peroxisome proliferator-activated receptor γ is a target for halogenated analogs of bisphenol A. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2014 | Environmental health perspectives, Dec, Volume: 122, Issue:12 | Structural and functional profiling of environmental ligands for estrogen receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (34)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (26.47) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.11
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.11) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 35 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||